Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880387 | 0.89 | ABCB1 (0.35) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL2012307 | 0.89 | ABCB1 (0.35) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL29451096 | 0.88 | ABCB1 (0.42) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL2006800 | 0.88 | ABCB1 (0.42) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL113139 | 0.88 | ABCB1 (0.42) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL25373810 | 0.88 | ABCB1 (0.42) | ABCB1KCNA5ABCC9KDM4EHSD17B10 | |
| SCHEMBL2875626 | 0.86 | KCNA5 (0.34) | ABCB1KCNA5ABCC9 | |
| SCHEMBL2004908 | 0.86 | KCNA5 (0.34) | ABCB1KCNA5ABCC9 | |
| SCHEMBL2869869 | 0.81 | IDO1 (0.37) | ABCB1ABCC9 | |
| SCHEMBL2869871 | 0.81 | IDO1 (0.37) | ABCB1ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | claimed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | claimed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | ABCB1 647/4885KCNA5 101/4885ABCC9 10/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ABCB1 580/4885KCNA5 67/4885ABCC9 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.